SCHEMBL4407110

SCHEMBL4407110

COC(=O)c1cccc(/C=C/c2cccc(C(=O)OC)c2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 5/20 0.68
GRIN2D O15399 1/20 0.59
GRIN3B O60391 1/20 0.59
GRIN1 Q05586 1/20 0.59
GRIN2A Q12879 1/20 0.59
GRIN2B Q13224 1/20 0.59
GRIN2C Q14957 1/20 0.59
GRIN3A Q8TCU5 1/20 0.59
PTPN1 P18031 1/20 0.56
TSHR P16473 1/20 0.55
LOXL2 Q9Y4K0 1/20 0.54
CYP4F2 P78329 1/20 0.53
CYP4A11 Q02928 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
RAB9A P51151 3/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP1A2 P05177 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11222093 1.00 P4HB (0.68) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL13926058 0.96 P4HB (0.64) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL24411012 0.95 P4HB (0.62) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1926762 0.95 P4HB (0.62) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1926761 0.95 P4HB (0.62) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL29496462 0.95 P4HB (0.62) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL850749 0.91 P4HB (0.62) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL13711691 0.91 P4HB (0.62) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL850750 0.91 P4HB (0.62) P4HBGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL9000311 0.90 P4HB (0.58) P4HBGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed
US-4356292-A FROM ACID CHLORIDE OF BIS-M-CARBOXYPHENYLACETYLENE, DIPHENYL ETHER, ISOPHTHALOYL CHLORIDE, 4,4'-DIPHENOXYDIPHENYL SULFONE THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 1982-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 P4HB 2556/4885GRIN2D 1554/4885GRIN3B 812/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A P4HB 2723/4885GRIN2D 1920/4885GRIN3B 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.